Peripheral blood progenitor cell transplantation

Economic issues

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

High-dose chemotherapy with autologous hematopoietic stem cell rescue is an expensive procedure. It is associated with improved long-term survival in many patients with cancer, but concern is growing about its cost and cost- effectiveness. The cost-effectiveness of high-dose chemotherapy depends largely on the magnitude of the difference in survival between it and standard-dose chemotherapy. Several economic analyses reported that the cost- effectiveness ratio of high-dose chemotherapy in the treatment of breast cancer is in the range of or slightly higher than that reported for other widely accepted medical interventions. Most centers are evaluating new strategies to reduce the overall cost of this therapy, including using peripheral blood progenitor cells rather than bone marrow-derived stem cells, optimizing the collection of peripheral blood progenitor cells, and shifting care from the inpatient to the outpatient setting.

Original languageEnglish (US)
JournalPharmacotherapy
Volume18
Issue number1
StatePublished - Feb 12 1998

Fingerprint

Cell Transplantation
Blood Cells
Stem Cells
Economics
Cost-Benefit Analysis
Drug Therapy
Costs and Cost Analysis
Survival
Hematopoietic Stem Cells
Inpatients
Outpatients
Bone Marrow
Breast Neoplasms
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Peripheral blood progenitor cell transplantation : Economic issues. / Yee, Gary C.

In: Pharmacotherapy, Vol. 18, No. 1, 12.02.1998.

Research output: Contribution to journalArticle

@article{13a9153f0e8d4e218e55c8f3a8ca1e0d,
title = "Peripheral blood progenitor cell transplantation: Economic issues",
abstract = "High-dose chemotherapy with autologous hematopoietic stem cell rescue is an expensive procedure. It is associated with improved long-term survival in many patients with cancer, but concern is growing about its cost and cost- effectiveness. The cost-effectiveness of high-dose chemotherapy depends largely on the magnitude of the difference in survival between it and standard-dose chemotherapy. Several economic analyses reported that the cost- effectiveness ratio of high-dose chemotherapy in the treatment of breast cancer is in the range of or slightly higher than that reported for other widely accepted medical interventions. Most centers are evaluating new strategies to reduce the overall cost of this therapy, including using peripheral blood progenitor cells rather than bone marrow-derived stem cells, optimizing the collection of peripheral blood progenitor cells, and shifting care from the inpatient to the outpatient setting.",
author = "Yee, {Gary C}",
year = "1998",
month = "2",
day = "12",
language = "English (US)",
volume = "18",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Peripheral blood progenitor cell transplantation

T2 - Economic issues

AU - Yee, Gary C

PY - 1998/2/12

Y1 - 1998/2/12

N2 - High-dose chemotherapy with autologous hematopoietic stem cell rescue is an expensive procedure. It is associated with improved long-term survival in many patients with cancer, but concern is growing about its cost and cost- effectiveness. The cost-effectiveness of high-dose chemotherapy depends largely on the magnitude of the difference in survival between it and standard-dose chemotherapy. Several economic analyses reported that the cost- effectiveness ratio of high-dose chemotherapy in the treatment of breast cancer is in the range of or slightly higher than that reported for other widely accepted medical interventions. Most centers are evaluating new strategies to reduce the overall cost of this therapy, including using peripheral blood progenitor cells rather than bone marrow-derived stem cells, optimizing the collection of peripheral blood progenitor cells, and shifting care from the inpatient to the outpatient setting.

AB - High-dose chemotherapy with autologous hematopoietic stem cell rescue is an expensive procedure. It is associated with improved long-term survival in many patients with cancer, but concern is growing about its cost and cost- effectiveness. The cost-effectiveness of high-dose chemotherapy depends largely on the magnitude of the difference in survival between it and standard-dose chemotherapy. Several economic analyses reported that the cost- effectiveness ratio of high-dose chemotherapy in the treatment of breast cancer is in the range of or slightly higher than that reported for other widely accepted medical interventions. Most centers are evaluating new strategies to reduce the overall cost of this therapy, including using peripheral blood progenitor cells rather than bone marrow-derived stem cells, optimizing the collection of peripheral blood progenitor cells, and shifting care from the inpatient to the outpatient setting.

UR - http://www.scopus.com/inward/record.url?scp=0031964222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031964222&partnerID=8YFLogxK

M3 - Article

VL - 18

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 1

ER -